Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Eine offene Studie zur Untersuchung von ECUR-506 bei männlichen Babys unter 9 Monaten mit neonatal beginnendem OTC-Mangel (OTC-HOPE)

29. September 2026 aktualisiert von: iECURE, Inc.

Eine erste offene Dosiseskalationsstudie der Phase I/II am Menschen zur Bewertung der Sicherheit und Wirksamkeit einer einzelnen intravenösen (IV) Verabreichung von ECUR-506 bei Männern unter 9 Monaten mit genetisch bestätigtem neonatalen Beginn Ornithin-Transcarbamylase (OTC)-Mangel

Ornithine Transcarbamylase (OTC) deficiency, the most common urea cycle disorder, is an inherited metabolic disorder caused by a genetic defect in a liver enzyme responsible for detoxifying of ammonia. Individuals with OTC deficiency can develop elevated levels of ammonia in the blood, potentially resulting in severe consequences, including cumulative and irreversible neurological damage, coma, and death. The most severe form presents shortly after birth and occurs more commonly in boys than girls.

This is a Phase 1/2/3, open-label, multicenter study evaluating the safety, efficacy, and dose of ECUR-506 in male babies with neonatal-onset OTC deficiency. The primary objective is to evaluate the safety, tolerability, and efficacy of up to three dose levels of ECUR-506 following intravenous (IV) administration of a single dose.

Studienübersicht

Status

Aktiv, nicht rekrutierend

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

The study drug, ECUR-506, is an investigational gene editing therapy. Gene editing is an approach used to repair, replace, or introduce functional copies of genes that are not working properly. ECUR-506 contains a functional copy of the OTC gene, along with a gene to encode an editing enzyme that enables insertion of the OTC gene into the genome. The study drug is administered as a single IV infusion. Because genes cannot enter cells on their own, ECUR-506 uses a delivery system based on adeno-associated virus (AAV), a commonly used viral vector, to transport the genetic material into cells.

Studientyp

Interventionell

Einschreibung (Geschätzt)

20

Phase

  • Phase 3

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • New South Wales
      • Sydney, New South Wales, Australien
        • The Children's Hospital at Westmead
    • Victoria
      • Melbourne, Victoria, Australien, 3052
        • The Royal Children's Hospital
      • Barcelona, Spanien, 08950
        • Hopsital Sant Joan de Deu
      • Madrid, Spanien, 28041
        • Hospital Universitario 12 de Octubre
    • California
      • Los Angeles, California, Vereinigte Staaten, 90095
        • UCLA Mattel Children's Hospital
    • Colorado
      • Aurora, Colorado, Vereinigte Staaten, 80045
        • Children's Hospital of Colorado, Anshutz Medical Campus
    • Georgia
      • Atlanta, Georgia, Vereinigte Staaten, 30322
        • Emory University School of Medicine
    • Illinois
      • Chicago, Illinois, Vereinigte Staaten, 60611
        • Ann & Robert H. Lurie Children's Hospital of Chicago
    • New York
      • New York, New York, Vereinigte Staaten, 10029
        • Icahn School of Medicine at Mount Sinai
    • Oregon
      • Portland, Oregon, Vereinigte Staaten, 97239
        • Oregon Health and Science University
      • London, Vereinigtes Königreich
        • Great Ormond Street Hospital
      • Newcastle upon Tyne, Vereinigtes Königreich
        • The Newcastle upon Tyne Hospitals NHS Foundation Trust- Great North Children's Hospital

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

1 Tag bis 7 Monate (Kind)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Männlich

Beschreibung

Key Inclusion Criteria:

  1. Male sex
  2. Gestational or adjusted (corrected) gestational age ≥ 37 weeks
  3. Age at screening is 24 hours to 7 months
  4. Weight ≥ 3.5 kg and ≤ 13.5 kg at screening
  5. Has received age-appropriate vaccinations
  6. Genetically confirmed OTCD defined by genetic confirmation of an OTC variant (pathogenic or likely pathogenic) associated with severe neonatal OTCD defined below in Inclusion Criteria #7 or has the same OTC variant as a family member who had severe neonatal OTCD within first week of life.
  7. Severe neonatal OTCD defined by hyperammonemic crisis with elevated ammonia level of >560 μmol/L and clinical symptoms within first week of life, and currently receiving treatment with both dietary protein restriction and nitrogen scavenger therapy.
  8. Current or historical biochemical profile consistent with OTCD
  9. Participant's parent(s)/LAR must be able to comprehend and be willing to provide a signed IRB/IEC-approved ICF.

Key Exclusion Criteria:

  1. Neonatal diagnosis of severe to profound Hypoxic Ischemic Encephalopathy due to birth injury
  2. Requiring urgent liver transplant due to liver failure as assessed by the PI.
  3. Contiguous gene deletion involving the OTC gene and including at least the CYBB gene on the telomeric side or the TSPAN7 gene on the centromeric side.
  4. Known or suspected major organ injury/dysfunction/anomalies.
  5. Vital sign and laboratory abnormalities outside of reference ranges.
  6. Treatment with any other gene therapy or gene editing therapy
  7. Co-enrollment in any other study unless approved by the sponsor.
  8. Any condition, that in the opinion of the Investigator, would compromise the safety of the participant or study data
  9. Documented vertical transmission of HepA/HepB/HepC
  10. Documented in-utero teratogen, substance, and/or alcohol exposure, which in the opinion of the Investigator may increase the participant's risk of developmental delays, congenital anomalies, and/or significant medical complications

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Nicht randomisiert
  • Interventionsmodell: Sequenzielle Zuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Low Dose Level

Participants will receive the Low Dose of ECUR-506 delivered one time via IV Infusion.

ECUR-506 is a gene editing treatment delivering a gene encoding the editing enzyme and an OTC gene.

Experimental: Intermediate Dose Level

Participants will receive an intermediate dose of ECUR-506 delivered on time via IV infusion

ECUR-506 is a gene editing treatment delivering a gene encoding the editing enzyme and an OTC gene.

Experimental: High Dose Level

Participants will receive a higher dose of ECUR-506 delivered one time via IV infusion.

ECUR-506 is a gene editing treatment delivering a gene encoding the editing enzyme and an OTC gene.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Treatment-emergent adverse events (incidence, severity, seriousness, and relatedness)
Zeitfenster: Over 24 weeks post infusion

Toxicity is graded in accordance with the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Adverse events (AEs) are reported based on clinical laboratory tests, vital signs, physical examinations, Pediatric Neurologist exam parameters, electrocardiograms, and any other medically indicated assessments from the time informed consent is signed through the end of the safety follow-up period.

AEs are considered to be treatment emergent (TEAE) if they occur or worsen in severity following the administration of the study treatment. TEAEs are considered treatment-related if relationship to study drug is possibly related, probably related, or definitely related.

Over 24 weeks post infusion
Physical exam parameters
Zeitfenster: Assessed as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.

Safety- (Includes PI assessment of General Appearance, Dermatological, HEENT, Lymphatic, Respiratory, Cardiovascular, Gastrointestinal, Musculoskeletal, Neurological (Cranial Nerve Function, Motor System Function, Sensory System Function, Primitive Reflexes))

Assessed as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
Vital sign parameters
Zeitfenster: Assessed as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.

Safety- (Includes PI assessment of Systolic Blood Pressure, Diastolic Blood Pressure, Pulse Rate, Respiratory Rate, Temperature)

Assessed as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
Pediatric neurologist exam parameters
Zeitfenster: Assessed as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.

Safety- (Includes Pediatric Neurologist assessment of Neurological status by review of Cranial Nerve Function, Motor System Function, Sensory System Function, Primitive Reflexes.)

Assessed as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
Blood safety tests including hematology, serum chemistry, liver function tests, coagulation tests
Zeitfenster: as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.

Safety- (Blood Safety tests to be reviewed in relation to established normal ranges for each assessment for the applicable age group)

as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
Urinalysis evaluations
Zeitfenster: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.

Toxicity is graded in accordance with the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Adverse events (AEs) are reported based on clinical laboratory tests, vital signs, physical examinations, electrocardiograms, and any other medically indicated assessments from the time informed consent is signed through the end of the safety follow-up period.

AEs are considered to be treatment emergent (TEAE) if they occur or worsen in severity following the administration of the study treatment. TEAEs are considered treatment-related if relationship to study drug is possibly related, probably related, or definitely related.

Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
12 lead ECG parameters
Zeitfenster: as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.

Safety- (Includes PI review of Heart Rate, PR Interval, RR Interval, QRS Duration, QT Interval, QTcF Interval, Overall Interpretation)

as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
Complete clinical response
Zeitfenster: Over 24 weeks post infusion

Discontinuation of scavenger medication for a minimum duration of 28 days without reductions in prescribed daily protein intake during this time period by end of study.

Over 24 weeks post infusion

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Number of HAEs/person-year
Zeitfenster: Day 1 post dose through Week 24

Key Secondary Endpoint: Pharmacodynamics and Efficacy

Day 1 post dose through Week 24
qPCR measurement to evaluate the clearance of both vectors in body fluids over time
Zeitfenster: Over 24 weeks post infusion

Supportive Secondary Endpoint: Pharmacokinetics

Over 24 weeks post infusion
Incidence of hyperammonemic episode (HAE)
Zeitfenster: Over 24 weeks post infusion

Supportive Secondary Endpoint: Pharmacodynamics and Efficacy

Over 24 weeks post infusion
Incidence and number of hyperammonemic episodes (HAE/HAC) resulting in hospitalization
Zeitfenster: Over 24 weeks post infusion

Supportive Secondary Endpoint: Pharmacodynamics and Efficacy

Over 24 weeks post infusion
Overall and by hospitalization severity (Mild: adjustment of dietary protein intake and oral scavenger medication / Moderate: cessation of dietary protein intake and initiation of IV scavenger therapy / Severe: requirement for hemodialysis)
Zeitfenster: Will be assessed Day 1 post dose through Wk 24 on all enrolled and dosed participants

Supportive Secondary Endpoint: Pharmacodynamics and Efficacy.

Will be assessed Day 1 post dose through Wk 24 on all enrolled and dosed participants
Duration of hospitalization for each HAE/HAC
Zeitfenster: Over 24 weeks post infusion

Supportive Secondary Endpoint: Pharmacodynamics and Efficacy

Over 24 weeks post infusion
Requirement for Intensive Care Unit (ICU) care during hospitalization for each HAE/HAC
Zeitfenster: Over 24 weeks post infusion

Supportive Secondary Endpoint: Pharmacodynamics and Efficacy

Over 24 weeks post infusion
Time to liver transplant from dosing to end of study (EOS)
Zeitfenster: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.

Supportive Secondary Endpoint: Efficacy

Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
Transplant free survival
Zeitfenster: Time to lever transplant or any-cause death from dosing to EOS

Supportive Secondary Endpoint: Efficacy

Time to lever transplant or any-cause death from dosing to EOS
Overall survival
Zeitfenster: Time to any-cause death from dosing to EOS

Supportive Secondary Endpoint: Efficacy

Time to any-cause death from dosing to EOS
Achieving and maintaining complete clinical response through end of study
Zeitfenster: Over 24 weeks post infusion

Supportive Secondary Endpoint: Efficacy

Over 24 weeks post infusion
Scavenger drug dose
Zeitfenster: Over 24 weeks post infusion

Supportive Secondary Endpoint: Efficacy

Over 24 weeks post infusion
Dietary protein intake g/kg/day
Zeitfenster: Supportive Secondary: Over 24 weeks post infusion

Supportive Secondary Endpoint: Efficacy

Supportive Secondary: Over 24 weeks post infusion
Blood urea nitrogen measurements
Zeitfenster: Over 24 weeks post infusion

Supportive Secondary Endpoint: Pharmacodynamics

Over 24 weeks post infusion

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Clinical Response (CR) defined as reduction in baseline standard of care therapy
Zeitfenster: Assessed at Week 24

Efficacy

Assessed at Week 24
Serum Neurofilament Light Chain
Zeitfenster: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.

Safety

Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
Number of participants with antibodies to AAVrh79 capsid in blood
Zeitfenster: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.

Pharmacodynamics

Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
Number of participants with antibodies to hOTC transgene in blood
Zeitfenster: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.

Pharmacodynamics

Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
Number of participants with antibodies to M2PCSK9 transgene in blood
Zeitfenster: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.

Pharmacodynamics

Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
Incidence and time to medical management adjustments based on iECURE guidance (protein diet or scavenger medication)
Zeitfenster: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.

Efficacy

Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
Fasting plasma ammonia
Zeitfenster: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.

Pharmacodynamics

Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
Fasting plasma citrulline and fasting plasma glutamine levels
Zeitfenster: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.

Pharmacodynamics

Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
Serum PCSK9
Zeitfenster: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.

Pharmacodynamics

Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
Urinary excretion of phenylacetate metabolites
Zeitfenster: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.

Urinary phenylacetate (mcg/mL), urinary phenylacetylglutamine (mcg/mL), urinary phenylacetate/ phenylglutamine ratio.

Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
Urinary excretion of orotic acid metabolites.
Zeitfenster: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.

Urinary orotic acid (mmol/ mol creatinine), urinary uracil (mmol/mol creatinine).

Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
Urinary nitrogen to urinary creatinine ratio.
Zeitfenster: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.

Urinary nitrogen to urinary creatinine ratio (mg/dL)

Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
Change from baseline at Week 24 post infusion in length.
Zeitfenster: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.

Length measured in centimeters.

Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
Change from baseline at Week 24 post infusion in weight.
Zeitfenster: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.

Weight measured in kilograms.

Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
Percent liver transduction via ISH/IF (in-situ hybridization / Immunofluorescence)"at Wk 24 collected by liver biopsy.
Zeitfenster: The following will be assessed at Week 24 if liver biopsy tissue sample is sufficient.

Pharmacodynamics

The following will be assessed at Week 24 if liver biopsy tissue sample is sufficient.
Assess the potential on and "off" target editing by amplicon-seq in liver tissue samples of participants who received ECUR-506.
Zeitfenster: The following will be assessed at week 24 if liver biopsy tissue sample is sufficient.

Pharmacodynamics

The following will be assessed at week 24 if liver biopsy tissue sample is sufficient.
Assess potential off-target editing with AAV vector ITR insertion by ITR-seq in liver tissue samples of participants who received ECUR-506
Zeitfenster: The following will be assessed at Week 24 if liver biopsy tissue sample is sufficient.

Pharmacodynamics

The following will be assessed at Week 24 if liver biopsy tissue sample is sufficient.
Assess for potential genetic changes in the liver tissue, collected by liver biopsy, through long read sequencing, in participants who have received ECUR-506
Zeitfenster: The following will be assessed at Week 24 if liver biopsy tissue sample is sufficient.

Pharmacodynamics

The following will be assessed at Week 24 if liver biopsy tissue sample is sufficient.
With an observed genetic safety signal, genetic analysis of Whole Blood DNA may be performed on samples collected and stored at screening and week 24, in the event of an observed genomic safety signal.
Zeitfenster: Will be assessed Day 1 post dose through Wk 24 on all enrolled and dosed participants.

Safety

Will be assessed Day 1 post dose through Wk 24 on all enrolled and dosed participants.
Change from baseline at Week 24 post infusion in Bayley Scales of Infant and Toddler Development 4th Ed (BSID-4) for the Cognitive, Language, and Motor scales
Zeitfenster: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.

Total Raw Scores, Growth Score Values (GSVs), and Age Equivalent Scores will be analyzed; Raw Scores range 0-162; GSVs range 428-599; Age Equivalent Scores range 1-42 months; a higher score reflects a higher level of skill.

Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
Quality of Life, as measured by the Pediatric QOL inventory Infant Scale (PedsQL-IS)
Zeitfenster: Will be assessed Day 1 post dose through Wk 24 on all enrolled and dosed participants.

Quality of Life

Will be assessed Day 1 post dose through Wk 24 on all enrolled and dosed participants.

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Studienleiter: George Diaz, M.D., Ph.D, iECURE, Inc.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

8. April 2024

Primärer Abschluss (Geschätzt)

1. Dezember 2027

Studienabschluss (Geschätzt)

1. Dezember 2027

Studienanmeldedaten

Zuerst eingereicht

19. Dezember 2023

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

2. Februar 2024

Zuerst gepostet (Tatsächlich)

13. Februar 2024

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

30. September 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

29. September 2026

Zuletzt verifiziert

1. September 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • ECUR-506-OTC-101
  • OTC-HOPE (Andere Kennung: iECURE, Inc.)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .